Abcellera Biologics - Common Shares (ABCL) closed at $11.13 on November 5, 2026, down 9.4% from the previous close, on volume of 3,907,487 shares (30-day average 4,340,708).
Data as of November 5, 2026.
5-Nov-2026
AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026
Business Wire (Thu, 5-Nov 4:05 PM ET)
AbCellera to Present at Upcoming Investor Conferences in November 2026
Business Wire (Thu, 22-Oct 4:05 PM ET)
ABCL Spotlight: Phase 2 Data Show ABCL635 Cut Vasomotor Symptoms by 8.8 Per Day at Week Four
Market Chameleon (Thu, 22-Oct 3:12 AM ET)
Globe Newswire (Wed, 21-Oct 10:00 AM ET)
Market Chameleon (Fri, 9-Oct 3:55 AM ET)
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
Business Wire (Thu, 8-Oct 4:05 PM ET)
AbCellera sets November 9 date for Q3 2026 results and a 3:00 p.m. Pacific earnings call
Market Chameleon (Fri, 2-Oct 5:04 AM ET)
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
Business Wire (Thu, 1-Oct 4:05 PM ET)
Business Wire (Wed, 16-Sep 4:05 PM ET)
Globe Newswire (Wed, 19-Aug 8:56 AM ET)
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Abcellera Biologics - Common Shares trades on the NASDAQ stock market under the symbol ABCL.
As of November 5, 2026, ABCL stock price declined to $11.13 with 3,907,487 million shares trading.
ABCL has a beta of 2.53, meaning it tends to be more sensitive to market movements. ABCL has a correlation of 0.09 to the broad based SPY ETF.
ABCL has a market cap of $3.61 billion. This is considered a Mid Cap stock.
Last quarter Abcellera Biologics - Common Shares reported $4 million in Revenue and -$.18 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.01.
In the last 3 years, ABCL traded as high as $15.02 and as low as $1.89.
The top ETF exchange traded funds that ABCL belongs to (by Net Assets): IBB, IDNA, SPDW, FDT, ONEQ.
ABCL has outperformed the market in the last year with a return of +128.5%, while the SPY ETF gained +9.7%. In the last 3 month period, ABCL beat the market returning +82.8%, while SPY returned -4.7%. However, in the most recent 2 weeks ABCL has underperformed the stock market by returning -9.1%, while SPY returned -5.2%.
ABCL support price is $11.61 and resistance is $12.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABCL shares will trade within this expected range on the day.
